Biotech Scorecard: My Best and Worst Calls

I was early in predicting that ImClone Systems would be bought for $70 a share, although I had no idea the acquiror would be Eli Lilly(LLY Quote).

As for columns and calls I wish I could take back, there was my prediction for a profitable sale of Middlebrook Pharmaceuticals(MBRK Quote) to some larger specialty pharmaceutical company. That takeout never happened.

I was a big fan of Progenics(PGNX Quote) based on high hopes for the commercial launch of its bowel drug Relistor. Unfortunately, doctors haven't been as excited about the drug as me.

I boldly predicted the October and December approval of AMAG Pharmaceuticals'(AMAG Quote) iron replacement therapy ferumoxytol. Neither happened, although I believe the third shot at approval early next year will be the charm. Or, so I hope.

Grading that last call will have to wait for next year's report card. Happy New Year!